PROTAC ATR degrader-3

PROTAC ATR degrader-3 是一种基于 CRBN 的强效 ATR PROTAC 降解剂(DC50 = 127 nM),同时可降解 CHK1(DC50 = 135 nM),能抑制癌细胞的增殖、迁移与侵袭,诱导细胞凋亡 (apoptosis),并引发 S 期阻滞与 DNA 损伤,在 LoVo 异种移植小鼠模型中可实现肿瘤生长抑制且无明显毒性,可用于结直肠癌的相关研究(粉色:ATR 配体 (MS-T79885);蓝色:Cereblon 配体 (MS-O43018);黑色:连接子)。
PROTAC ATR degrader-3
产品编号: MS-M60111 分子式: C41H38N8O6 分子量: 738.79
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

PROTAC ATR degrader-3 是一种基于 CRBN 的强效 ATR PROTAC 降解剂(DC50 = 127 nM),同时可降解 CHK1(DC50 = 135 nM),能抑制癌细胞的增殖、迁移与侵袭,诱导细胞凋亡 (apoptosis),并引发 S 期阻滞与 DNA 损伤,在 LoVo 异种移植小鼠模型中可实现肿瘤生长抑制且无明显毒性,可用于结直肠癌的相关研究(粉色:ATR 配体 (MS-T79885);蓝色:Cereblon 配体 (MS-O43018);黑色:连接子)。

生物实验数据

生物活性 PROTAC ATR degrader-3 is a potent CRBN-based ATR PROTAC degrader (DC50 = 127 nM) that also degrades CHK1 (DC50 = 135 nM), inhibits cancer cell proliferation, migration, and invasion, induces apoptosis, and triggers S-phase arrest and DNA damage, achieving tumor growth inhibition in a LoVo xenograft mouse model without obvious toxicity, and can be used for research on colorectal cancer (pink: ATR ligand (MS-T79885); blue: Cereblon ligand (MS-O43018); black: linker).
IC50 & Target

Cereblon

 

ATR

127 nM (DC50)

Chk1

135 nM (DC50)

Caspase 3

 

Bcl-2

 

体外研究
(In Vitro)

PROTAC ATR degrader-3 (Compound A12) 在无细胞实验中可强效且选择性地抑制 ATR 激酶,其 IC50 为 2.7 ± 0.5 nM,对 DNA-PK、PI3Kα 和 ATM 的活性极低。
PROTAC ATR degrader-3 (31 nM-5 μM; 8-72 h) 可在 LoVo 细胞中诱导强效的、时间和浓度依赖性的蛋白酶体介导的 ATR 降解,72 h 后其 DC50 为 127 nM,Dmax 为 72%。
PROTAC ATR degrader-3 (72 h) 可对 SW480 (DC50 = 140 nM, Dmax = 95%) 和 HCT116 (DC50 = 48 nM, Dmax = 77%) 结直肠癌细胞中的 ATR 产生强效降解作用。
PROTAC ATR degrader-3 (0-10 μM; 16-72 h) 可在 LoVo 细胞中诱导强效的、浓度依赖性的蛋白酶体介导的 CHK1 降解,作用 72 h 后其 DC50 为 135 nM,Dmax 为 70%。
PROTAC ATR degrader-3 (72 h) 可诱导 SW480 结直肠癌细胞中 CHK1 降解 (DC50 = 426 nM, Dmax = 90%),也可诱导 HCT116 结直肠癌细胞中 CHK1 降解 (DC50 = 95 nM, Dmax = 74%)。
PROTAC ATR degrader-3 (72 h) 可强效抑制 LoVo 结直肠癌细胞的增殖,其 IC50 为 0.055 ± 0.010 μM,对 SW480 (IC50 = 0.37 μM)、HCT116 (IC50 = 2.774 μM) 及正常 NCM460 (IC50 = 13.161 μM) 细胞的活性较低。
PROTAC ATR degrader-3 (250 nM; 48 h, with 2 μM MG132 co-treatment) 可增强 LoVo 细胞中 ATR 的多泛素化修饰,证实其为泛素依赖的蛋白酶体降解途径。
PROTAC ATR degrader-3 (0.5-2.0 μM; 48 h) 处理 LoVo 细胞 48 h 后可诱导 S 期细胞周期阻滞,在 1.0 μM 浓度下 S 期细胞比例最高可达 38.05%。
PROTAC ATR degrader-3 (0.5-4.0 μM; 48 h) 可呈剂量依赖性诱导 LoVo 细胞发生凋亡,同时伴随 caspase 介导的凋亡通路激活。
PROTAC ATR degrader-3 (0.5-2.0 μM; 10 days) 可在 10 天内强效且呈剂量依赖性地抑制 LoVo 细胞的集落形成。
PROTAC ATR degrader-3 (0.5-2.0 μM; 24-48 h) 可剂量依赖性地抑制 LoVo 细胞的迁移侵袭和侵袭。
PROTAC ATR degrader-3 (0.5-4.0 μM; 24 h) 可在 24 h 后诱导 LoVo 细胞中剂量依赖性的 DNA 损伤累积,同时伴随 γH2AX 表达增多。

Western Blot Analysis

Cell Line: LoVo human colorectal cancer cells
Concentration: 31, 62, 125. 250, 500, 1000, 2000, 5000 nM
Incubation Time: 8, 16, 24, 48, 72 h
Result: Induced 60 ± 5% ATR degradation at 0.1 μM and 78 ± 3% degradation at 0.5 μM after 72 h.
Achieved a DC50 of 127 nM and maximum degradation (Dmax) of 72% after 72 h.
Induced significant ATR degradation at 250 nM by 48 h.
Blocked ATR degradation when cells were pre-treated with MG132 (MS-L06849) or lenalidomide.

Western Blot Analysis

Cell Line: LoVo human colorectal cancer cells
Concentration: 0-10000 nM (72 h); 1 μM (16 h, with 2 h pre-incubation with 2 μM MG132, 2 μM lenalidomide, or 2 μM C1); 0.5-4 μM (24 h)
Incubation Time: 16 h (with pre-treatment); 24 h; 72 h
Result: Induced concentration-dependent CHK1 degradation with a DC50 of 135 nM and Dmax of 70% after 72 h.
Blocked CHK1 degradation when cells were pre-treated with MG132 or lenalidomide.
Reduced CHK1 protein levels at concentrations ≥0.5 μM after 24 h.

Western Blot Analysis

Cell Line: LoVo human colorectal cancer cells
Concentration: 250 nM (with 2 μM MG132 co-treatment)
Incubation Time: 48 h
Result: Markedly enhanced polyubiquitination of ATR protein, as shown by increased ubiquitin signal in immunoprecipitated ATR samples.

Cell Cycle Analysis

Cell Line: LoVo human colorectal cancer cells
Concentration: 0.5, 1.0, 2.0, 4.0 μM
Incubation Time: 48 h
Result: Induced S-phase arrest: 35.30% of cells in S-phase at 0.5 μM, 38.05% at 1.0 μM, 37.65% at 2.0 μM, compared to 29.11% in control cells.
Reduced G0-G1 phase population to 53.69% (0.5 μM), 50.79% (1.0 μM), 51.80% (2.0 μM), compared to 58.66% in control cells.

Apoptosis Analysis

Cell Line: LoVo human colorectal cancer cells
Concentration: 0.5-2.0 μM
Incubation Time: 48 h
Result: Induced dose-dependent apoptosis.
Increased levels of cleaved PARP1 and cleaved Caspase-3 in a concentration-dependent manner.
Reduced Bcl-2 levels.
体内研究
(In Vivo)

PROTAC ATR degrader-3 (Compound A12) (10-30 mg/kg;腹腔注射;每日 2 次;持续 32 天) 可在裸鼠中呈剂量依赖性地显著抑制 LoVo 结直肠癌异种移植物的生长,在 30 mg/kg 剂量下的最大 TGI 为 74%;且对小鼠体重无不良影响。

Animal Model: Nude mice with LoVo colorectal cancer xenograft (female, 7-8 weeks old)
Dosage: 10, 20, 30 mg/kg; 10 mg/kg (combination with Cetuximab)
Administration: i.p.; twice daily; 32 days; i.v. (cetuximab, every 4 days)
Result: Achieved 43% tumor growth inhibition (TGI) at 10 mg/kg monotherapy.
Achieved 57% TGI at 20 mg/kg monotherapy.
Achieved 74% TGI at 30 mg/kg monotherapy.
Achieved 81% TGI at 10 mg/kg in combination with Cetuximab (MS-F27523).
Caused no adverse effect on mouse body weight.
Downregulated ATR, p-ATR, CHK1, and p-CHK1 expression in tumor tissue.
Upregulated p-p53, p21, and γH2AX expression in tumor tissue.

化学信息

分子量 738.79
分子式 C41H38N8O6

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础